# OnCo record paper-imforte-lancet-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-imforte-lancet-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-imforte-lancet-2025" ;
  schema:name "Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial"@en ;
  schema:description "Published report from the IMforte trial registered as NCT05091567, in The Lancet (2025), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-imforte-lancet-2025/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s0140-6736(25)01011-6>, <https://pubmed.ncbi.nlm.nih.gov/40473449/>, <https://europepmc.org/article/MED/40473449>, <https://clinicaltrials.gov/study/NCT05091567> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s0140-6736(25)01011-6> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Paz-Ares L, Borghaei H, Liu SV, et al." ;
  onco:trials <https://onco.cc/trials/imforte/> ;
  onco:journals <https://onco.cc/journals/lancet/> .